Shuffling continues at Del Global
Leonard A. Trugman is out as CEO, president, and chair of the board at Del Global Technologies. Financial troubles led to the firing last month of the president and CFO of its Medical Systems Group (SCAN 2/14/01). Trugman “agreed to
Leonard A. Trugman is out as CEO, president, and chair of the board at Del Global Technologies. Financial troubles led to the firing last month of the president and CFO of its Medical Systems Group (SCAN 2/14/01). Trugman “agreed to resign” his position as an officer and director, according to the company, “to pursue other opportunities.” Meanwhile the company’s board elected Samuel E. Park as acting president and CEO, Thomas V. Gilboy as CFO, and Carole Murphy as corporate controller. Roger Winston was elected chair of the board. (George Solomon also resigned from the board, although his leaving is “unrelated to the foregoing,” according to the company.)
SNMMI: Can 18F-Fluciclovine PET/CT Bolster Detection of PCa Recurrence in the Prostate Bed?
June 24th 2025In an ongoing prospective study of patients with biochemical recurrence of PCa and an initial negative PSMA PET/CT, preliminary findings revealed positive 18F-fluciclovine PET/CT scans in over 54 percent of the cohort, according to a recent poster presentation at the SNMMI conference.
Could an Emerging PET Tracer be a Game Changer for Detecting Hepatocellular Carcinoma?
June 23rd 2025In addition to over 90 percent sensitivity in detecting hepatocellular carcinoma (HCC), the glypican-3 (GPC3) targeted PET tracer 68Ga-aGPC3-scFv appeared to be advantageous in identifying HCC tumors smaller than one centimeter, according to pilot study findings presented at the SNMMI conference.
SNMMI: What a New Meta-Analysis Reveals About Radiotracers for PET/CT Detection of PCa
June 22nd 2025While (68Ga)Ga-PSMA-11 offers a pooled sensitivity rate of 92 percent for prostate cancer, (18F)-based radiotracers may offer enhanced lesion detection as well as improved imaging flexibility, according to a meta-analysis presented at the Society for Nuclear Medicine and Molecular Imaging (SNMMI) conference.
